TABLE 3.
Correlation between FUT8 expression and clinicopathological factors in 92 patients with LUAD.
| Characteristics | FUT8 protein expression | p-value | |
|---|---|---|---|
| Low (N = 40) | High (N = 52) | ||
| Age, years | 61.35 ± 9.01 | 64.23 ± 10.44 | .168 |
| Sex | |||
| Male | 23 (42.5%) | 28 (46.2%) | .727 |
| Female | 17 (57.5%) | 24 (53.8%) | |
| Differentiation | |||
| Well/moderate | 28 (70.0%) | 29 (55.8%) | .163 |
| Poor | 12 (30.0%) | 23 (44.2%) | |
| Tumor status (T) | |||
| T1+T2 | 29 (72.5%) | 44 (84.6%) | .155 |
| T3+T4 | 11 (27.5%) | 8 (15.4%) | |
| Stage | |||
| I + II | 27 (67.5%) | 32 (61.5%) | .555 |
| III + IV | 13 (32.5%) | 20 (38.5%) | |
| Lymph node metastasis | |||
| Negative | 22 (55.0%) | 21 (40.4%) | .164 |
| Positive | 18 (45.0%) | 31 (59.6%) | |
| EGFR mutation | |||
| Negative | 33 (82.5%) | 38 (73.1%) | .286 |
| Positive | 7 (17.5%) | 14 (26.9%) | |
Values are mean ± SD (standard deviation) or n (%).
FUT8, fucosyltransferase 8; LUAD, lung adenocarcinoma; EGFR, epidermal growth factor receptor.